Remission induction in a case of refractory behçet disease with alemtuzumab

Journal of Clinical Rheumatology

Volumn 19, Issue 2, 2013, Pages 101-103

  Perez Pampin, Eva ^a   Campos Franco, Joaquin ^a   Blanco, Jorge ^a   Mera, Antonio ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA2B INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FAMCICLOVIR; INFLIXIMAB; MABCAMPATH 1H; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NYSTATIN; PENTAMIDINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTHRALGIA; ARTICLE; BEHCET DISEASE; BLINDNESS; BOLUS INJECTION; BONE MARROW BIOPSY; CASE REPORT; COMPASSIONATE USE; CORNEA ULCER; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; FEVER; FOLLOW UP; GENITAL SYSTEM DISEASE; GENITAL ULCER; GYNECOLOGICAL EXAMINATION; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; LEUKOPENIA; NEURITIS; NEUTROPHIL COUNT; OPHTHALMOSCOPY; OPTIC NEURITIS; OROGENITAL APHTHOSIS; PANNICULITIS; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION; SEIZURE; SKIN BIOPSY; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BEHCET SYNDROME; FEMALE; HUMANS; REMISSION INDUCTION; YOUNG ADULT;

EID: 84874946529     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318284735c     Document Type: Article

References (15)

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med. 1999;341:1284-1291
2. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662
3. Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol. 1994;47:313-317
4. Dearden CE, Mateus E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood. 2001;98:1721-1726
5. Amengual JE, Raphael BG. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2010;51:1347-1350
6. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267-4272
7. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801
8. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773
9. Lockwood CM, Hale G, Waldman H, et al. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003;42:1539-1544
10. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000;84:107-109
11. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35:3332-3342
12. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J. 2009;16:77-81
13. Elter T, Molnar I, Kuhlmann J, et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008;49:2256-2262
14. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691-1695
15. Botsios C, Sfriso P, Furlan A, et al. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149:284-286